Partners
INNOVATION PARTNER:
Almac has been supplying peptides to the research community and for clinical trials for > 20 years. The field of personalised cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs. Think Almac for peptide excellence.
EXPERTISE PARTNER:
At Personalis, our mission is to transform the active management of cancer through personalised testing. For personalised cancer therapies (PCT), ImmunoID NeXT™ powers individualised neoantigen-based therapy design, with NeXT Personal™ providing therapy response monitoring (e.g. an early indication of efficacy). NeXT Personal is designed to detect disease recurrence earlier than ever before, and to monitor ctDNA kinetics with unparalleled sensitivity, driving patient stratification, and enhancing biomarker strategy for drug development. We are driving a new paradigm for cancer management, guiding care from biopsy through the life of the patient, delivering advanced insights, even as cancer evolves over time.
INNOVATION PARTNER:
Your trusted end-to-end provider of personalized peptide cancer vaccines with 30+ years in peptide synthesis. With expanding facilities for GMP peptide manufacturing and aseptic fill and finish, we offer full peptide drug development: customized research-grade peptides, peptide drug substance and peptide drug product. In combination with our unmatched customer-service and manufacturing speed, you will execute your personalized vaccine trial faster with less worries. Simply contact us for a truly end-to-end peptide trial solution.
